mTOR pathway specialist Aadi Bioscience (Nasdaq: AADI) has secured US approval for its intravenously-administered oncology therapy Fyarro (sirolimus).
The decision makes Aadi, a Californian precision medicine company, the first to address a very rare and aggressive type of sarcoma, perivascular epithelioid cell tumor (PEComa).
The company reportedly plans to launch at the start of 2022 with a list price of around $39,000 per month.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze